Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

zPREDICTA, LabCorp ink collaboration
April 2020
SHARING OPTIONS:

SAN JOSE, Calif.—zPREDICTA Inc. and LabCorp have teamed up under the auspices of a strategic collaboration that will advance the adoption of zPREDICTA’s proprietary 3D cell culture platform for preclinical testing and research studies. The 3D models are tissue-specific as well as disease-specific for a broader range of in-vitro testing. Financial terms for the agreement were not released.
 
“Given our focus on precision medicine, particularly in the area of oncology, we are looking forward to working with zPREDICTA to develop and commercialize tumor-specific preclinical models based on its 3D cell culture technology,” said Dr. Steve Anderson, chief scientific officer for Covance, LabCorp’s drug development business. “Covance continues to invest in innovations that improve drug development. We believe the zPREDICTA 3D in-vitro models offer a more predictable method for early evaluation of responses to immuno-oncology therapies.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.